Anti-IL-8 抗体 [EPR26511-74] (ab289967)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR26511-74] to IL-8
- Suitable for: ICC/IF, Flow Cyt (Intra), IP, WB
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-IL-8 antibody [EPR26511-74]
IL-8 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR26511-74] to IL-8 -
由来種
Rabbit -
アプリケーション
適用あり: ICC/IF, Flow Cyt (Intra), IP, WBmore details
適用なし: IHC-P -
種交差性
交差種: Human -
免疫原
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
ポジティブ・コントロール
- WB: Wild-type treated PC-3, treated U-937, Untreated U-87 MG, U-87 MG treated with 1µM Thapsigargin for 24h. ICC/IF: Treated U-937 cells. Flow Cyt (intra): Treated U-937 cells, treated Human peripheral blood mononuclear cell (PBMC). IP: treated U-937 whole cell lysate
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
バッファー
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 0.05% BSA, 40% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EPR26511-74 -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Isotype control
-
Related Products
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab289967の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
ICC/IF |
1/100.
|
|
Flow Cyt (Intra) |
1/500.
|
|
IP |
1/30.
|
|
WB |
1/1000. Predicted molecular weight: 11 kDa.
|
特記事項 |
---|
ICC/IF
1/100. |
Flow Cyt (Intra)
1/500. |
IP
1/30. |
WB
1/1000. Predicted molecular weight: 11 kDa. |
ターゲット情報
-
機能
IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. It is released from several cell types in response to an inflammatory stimulus. IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively. -
配列類似性
Belongs to the intercrine alpha (chemokine CxC) family. -
翻訳後修飾
Several N-terminal processed forms are produced by proteolytic cleavage after secretion from at least peripheral blood monocytes, leukcocytes and endothelial cells. In general, IL-8(1-77) is referred to as interleukin-8. IL-8(6-77) is the most promiment form. -
細胞内局在
Secreted. - Information by UniProt
-
参照データベース
- Entrez Gene: 3576 Human
- Omim: 146930 Human
- SwissProt: P10145 Human
- Unigene: 624 Human
-
別名
- (Ala-IL-8)77 antibody
- (Ser-IL-8)72 antibody
- 9E3 antibody
see all
画像
-
All lanes : Anti-IL-8 antibody [EPR26511-74] (ab289967) at 1/1000 dilution
Lane 1 : Wild-type PC-3 (human prostate adenocarcinoma epithelial cell) whole cell lysate
Lane 2 : Wild-type PC-3 treated with 2µg/ml LPS for 5h, then treated with 5µg/ml Brefeldin A for 5h, whole cell lysate
Lane 3 : CXCL8 knockout PC-3 whole cell lysate
Lane 4 : CXCL8 knockout PC-3 treated with 2µg/ml LPS for 5h, then treated with 5µg/ml Brefeldin A for 5h, whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) at 1/10000 dilution
Predicted band size: 11 kDa
Observed band size: 11 kDaBlocking buffer and concentration was Intercept® (TBS) Blocking Buffer diluted with an equal volume of 0.1% TBS.
Diluting buffer was Intercept® (TBS) Blocking Buffer diluted with an equal volume of 0.1% TBST.
Lysates/proteins at 20 µg per lane.
Performed under reducing conditions.
False colour image of Western blot: Anti-IL-8 antibody [EPR26511-74] (ab289967) staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red.
In Western blot, ab289967 was shown to bind specifically to IL-8. A band was observed at 11 kDa in wild-type PC-3 cell lysates with no signal observed at this size in CXCL8 knockout cell lysates. To generate this image, wild-type and CXCL8 knockout PC-3 cell lysates were analyzed. First, samples were run on an SDS-PAGE gel then transferred onto an immobilon-FL PVDF membrane. Membranes were blocked in Intercept® (TBS) Blocking Buffer diluted with an equal volume of 0.1% TBS before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/10000 dilution. -
All lanes : Anti-IL-8 antibody [EPR26511-74] (ab289967) at 1/1000 dilution
Lane 1 : Untreated U-937 (human histiocytic lymphoma monocyte) whole cell lysate
Lane 2 : U-937 treated with TPA (100ng/mL) for 24 h, then treated with LPS (5 µg/mL) for 7 h with Brefeldin A (300 ng/mL) for the last 3 h, whole cell lysate
Lane 3 : Untreated U-87 MG (human glioblastoma-astrocytoma epithelial cell) whole cell lysate
Lane 4 : U-87 MG treated with 1µM Thapsigargin for 24h, whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 11 kDa
Observed band size: 11 kDa
Exposure time: 70 secondsBlocking and diluting buffer and concentration was 5% NFDM/TBST.
-
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized U-937 cells labelling IL-8 with ab289967 at 1/100 (5.87 µg/ml) dilution, followed by ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed antibody at 1/1000 (2 µg/mL) dilution (Green). Confocal image showing cytoplasmic staining is observed in U-937 cells treated with TPA (100 ng/mL) for 24 h, then LPS (5 µg/mL) for 7 h with Brefeldin A (300 ng/mL) for the last 3 h. ab195889 Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/200 (2.5µg/ml) dilution (Red). The Nuclear counterstain was DAPI (Blue).
Secondary antibody only control: Secondary antibody is ab150081 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed at 1/1000 (2 µg/mL) dilution.
-
Intracellular flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized U-937 (Human histiocytic lymphoma monocyte) treated with 100ng/ml TPA for 24 hours, then 5µg/ml LPS for 4 hours, and add 300ng/ml BFA for another 3h (Red) / Untreated control (Green) cells labelling IL-8 with ab289967 at 1/500 dilution (0.1µg) compared with a Rabbit monoclonal IgG (ab172730) (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). A Goat Anti-Rabbit IgG (Alexa Fluor® 488, ab150081) at 1/2000 dilution was used as the secondary antibody.
-
Intracellular flow cytometric analysis of 2% paraformaldehyde fixed, 0.1% saponin permeabilised human peripheral blood mononuclear cell (PBMC) treated with 1μg/ml Lipopolysaccharide (LPS) for 22 hours, then add 3uM Monensin for another 2h (Right). Untreated control (Left).
Primary antibody: ab289967, at 1/500 dilution.
Secondary antibody: Goat Anti-Rabbit IgG (Alexa Fluor® 488, ab150081) at 1/2000 dilution.
Scatter image shows specific IL-8 expression in LPS induced monocyte population.
-
IL-8 was immunoprecipitated from U937 (human histiocytic lymphoma monocyte) treated with 100ng/ml TPA for 24h then treated with 5 µg/ml LPS for 4h, and add 300 ng/ml BFA for another 3h, whole cell lysate with ab289967 at 1/30 dilution (2 µg in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab289967 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.
Lane 1: U937 (human histiocytic lymphoma monocyte) treated with 100 ng/ml TPA for 24h then treated with 5 µg/ml LPS for 4h, and add 300 ng/ml BFA for another 3h, whole cell lysate 10 µg
Lane 2: ab289967 IP in U937 treated with 100 ng/ml TPA for 24h then treated with 5 µg/ml LPS for 4h, and add 300 ng/ml BFA for another 3h, whole cell lysate
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab289967 in U937 treated with 100 ng/ml TPA for 24h then treated with 5 µg/ml LPS for 4h, and add 300 ng/ml BFA for another 3h, whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 50 seconds
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
Certificate of Compliance
参考文献 (3)
ab289967 は 3 報の論文で使用されています。
- Liu C et al. MicroRNA-485-3p Promotes the Inflammatory Response and Extracellular Matrix Deposition by Activating Wnt/β-Catenin Signaling in Human Airway Smooth Muscle Cells. Crit Rev Eukaryot Gene Expr 33:1-12 (2023). PubMed: 37183942
- Fan G et al. An immunosuppressive subtype of senescent tumor cells predicted worse immunotherapy response in lung adenocarcinoma. iScience 26:107894 (2023). PubMed: 37766998
- Piao H et al. A positive feedback loop between gastric cancer cells and tumor-associated macrophage induces malignancy progression. J Exp Clin Cancer Res 41:174 (2022). PubMed: 35562774